サマリー

中東とアフリカの鼻腔スプレー市場は、2023年から2030年の予測期間に5.4%のCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。

市場セグメンテーション

中東・アフリカの点鼻薬市場：製品タイプ別（充血除去点鼻薬、ステロイド点鼻薬、塩水・生理食塩水点鼻薬、その他）、容器設計（ポンプボトル、加圧キャニスター）、剤形（多剤、単位・単剤、二剤）、治療クラス（抗ヒスタミン、鼻ステロイド、肥満細胞阻害、抗コリン作用）、用途（鼻づまり、アレルギー性・非アレルギー性鼻炎、中枢神経系疾患、ワクチン接種、その他）、処方・入手方法（市販・処方）、エンドユーザー（在宅医療、病院、クリニック、地域医療）、国（南アフリカ、サウジアラビア、UAE、その他中東・アフリカ） 産業動向と2030年予測

中東・アフリカの鼻腔スプレー市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 鼻腔スプレーの治療用途の増加
- アレルギー疾患やCOVID-19などのパンデミックに対応した点鼻薬の需要増
市場関係者
中東・アフリカの鼻腔スプレー市場で事業を展開している主な市場関係者は以下の通りです：

- エマージェンシー
- Cipla Inc.
- サンド・インターナショナルGmbH（ノバルティス社傘下）
- アイトゥヘルス（アイトゥバイオファーマ社の子会社）
- バイエル社
- グラクソ・スミスクライン plc.
- アサーティオ・セラピューティクス・インク
- アウレナ・ラボラトリーズ
- ジェイ・ファーマシューティカルズ
- セント・ルナトゥス
- ウルトラテック インディア リミテッド
- キャタレント社（Catalent, Inc.
- Teva Pharmaceuticals USA, Inc. (Teva Pharmaceutical Industries Ltd.の子会社)
- ファイザー株式会社（Pfizer Inc.
- ヴィアトリス・インク
- リーフォード・ヘルスケアLtd
- アイシワリヤグループ

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 PRODUCT TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PORTER’S FIVE FORCES MODEL 42
4.2 PESTEL ANALYSIS 43
5 INDUSTRY INSIGHTS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET 44
5.1 INDUSTRY INSIGHTS 44
6 REGULATIONS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET 45
7 MARKET OVERVIEW 46
7.1 DRIVERS 48
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 48
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 48
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 49
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 50
7.2 RESTRAINTS 51
7.2.1 PRODUCT RECALLS 51
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 52
7.3 OPPORTUNITIES 53
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 53
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 53
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 54
7.4 CHALLENGES 54
7.4.1 REGULATORY HURDLES 54
7.4.2 ADDICTION TO NASAL SPRAY 55
8 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE 56
8.1 OVERVIEW 57
8.2 DECONGESTION NASAL SPRAY 60
8.3 STEROID NASAL SPRAY 61
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 62
8.5 OTHERS 63
9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN 64
9.1 OVERVIEW 65
9.2 PUMP BOTTLES 68
9.3 PRESSURIZED CANISTERS 69
10 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM 70
10.1 OVERVIEW 71
10.2 MULTI DOSE 74
10.3 UNIT/SINGLE DOSE 75
10.4 BI DOSE 76
11 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 78
11.1 OVERVIEW 79
11.2 ANTIHISTAMINE 82
11.3 NASAL STEROIDS 83
11.4 MAST CELL INHIBITOR 84
11.5 ANTICHOLINERGIC 85
12 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION 86
12.1 OVERVIEW 87
12.2 NASAL CONGESTION 90
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 91
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 92
12.5 VACCINATION 93
12.6 OTHERS 94
13 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 95
13.1 OVERVIEW 96
13.2 PRESCRIBED 99
13.3 OVER THE COUNTER 100
14 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER 102
14.1 OVERVIEW 103
14.2 HOME CARE SETTINGS 106
14.3 HOSPITALS 107
14.4 CLINICS 108
14.5 COMMUNITY HEALTH CARE 109
15 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY REGION 110
15.1 MIDDLE EAST AND AFRICA 111
15.1.1 SOUTH AFRICA 118
15.1.2 UAE 120
15.1.3 SAUDI ARABIA 122
15.1.4 REST OF MIDDLE EAST & AFRICA 124
16 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, COMPANY LANDSCAPE 125
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 125
17 SWOT ANALYSIS 126
18 COMPANY PROFILE 127
18.1 GLAXOSMITHKLINE PLC. 127
18.1.1 COMPANY SNAPSHOT 127
18.1.2 REVENUE ANALYSIS 127
18.1.3 COMPANY SHARE ANALYSIS 128
18.1.4 PRODUCT PORTFOLIO 128
18.1.5 RECENT DEVELOPMENTS 128
18.2 PFIZER INC. 130
18.2.1 COMPANY SNAPSHOT 130
18.2.2 REVENUE ANALYSIS 130
18.2.3 COMPANY SHARE ANALYSIS 131
18.2.4 PRODUCT PORTFOLIO 131
18.2.5 RECENT DEVELOPMENTS 131
18.3 EMERGENT 133
18.3.1 COMPANY SNAPSHOT 133
18.3.2 REVENUE ANALYSIS 133
18.3.3 COMPANY SHARE ANALYSIS 134
18.3.4 PRODUCT PORTFOLIO 134
18.3.5 RECENT DEVELOPMENT 134
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 135
18.4.1 COMPANY SNAPSHOT 135
18.4.2 REVENUE ANALYSIS 135
18.4.3 COMPANY SHARE ANALYSIS 136
18.4.4 PRODUCT PORTFOLIO 136
18.4.5 RECENT DEVELOPMENT 136
18.5 CATALENT, INC. 137
18.5.1 COMPANY SNAPSHOT 137
18.5.2 REVENUE ANALYSIS 137
18.5.3 COMPANY SHARE ANALYSIS 138
18.5.4 PRODUCT PORTFOLIO 138
18.5.5 RECENT DEVELOPMENTS 138
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 140
18.6.1 COMPANY SNAPSHOT 140
18.6.2 REVENUE ANALYSIS 140
18.6.3 PRODUCT PORTFOLIO 141
18.6.4 RECENT DEVELOPMENTS 141
18.7 AISHWARYA GROUP 142
18.7.1 COMPANY SNAPSHOT 142
18.7.2 PRODUCT PORTFOLIO 142
18.7.3 RECENT DEVELOPMENTS 142
18.8 ASSERTIO THERAPEUTICS, INC. 143
18.8.1 COMPANY SNAPSHOT 143
18.8.2 REVENUE ANALYSIS 143
18.8.3 PRODUCT PORTFOLIO 144
18.8.4 RECENT DEVELOPMENT 144
18.9 AURENA LABORATORIES. 145
18.9.1 COMPANY SNAPSHOT 145
18.9.2 PRODUCT PORTFOLIO 145
18.9.3 RECENT DEVELOPMENTS 145
18.10 BAYER AG 147
18.10.1 COMPANY SNAPSHOT 147
18.10.2 REVENUE ANALYSIS 147
18.10.3 COMPANY SHARE ANALYSIS 148
18.10.4 PRODUCT PORTFOLIO 148
18.10.5 RECENT DEVELOPMENTS 148
18.11 CIPLA INC. 150
18.11.1 COMPANY SNAPSHOT 150
18.11.2 REVENUE ANALYSIS 150
18.11.3 PRODUCT PORTFOLIO 151
18.11.4 RECENT DEVELOPMENT 151
18.12 J PHARMACEUTICALS. 152
18.12.1 COMPANY SNAPSHOT 152
18.12.2 PRODUCT PORTFOLIO 152
18.12.3 RECENT DEVELOPMENTS 152
18.13 LEEFORD HEALTHCARE LTD 153
18.13.1 COMPANY SNAPSHOT 153
18.13.2 PRODUCT PORTFOLIO 153
18.13.3 RECENT DEVELOPMENTS 153
18.14 ST. RENATUS. 154
18.14.1 COMPANY SNAPSHOT 154
18.14.2 PRODUCT PORTFOLIO 154
18.14.3 RECENT DEVELOPMENTS 154
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 155
18.15.1 COMPANY SNAPSHOT 155
18.15.2 REVENUE ANALYSIS 155
18.15.3 PRODUCT PORTFOLIO 156
18.15.4 RECENT DEVELOPMENTS 156
18.16 ULTRATECH INDIA LIMITED 157
18.16.1 COMPANY SNAPSHOT 157
18.16.2 PRODUCT PORTFOLIO 157
18.16.3 RECENT DEVELOPMENTS 157
18.17 VIATRIS INC. 158
18.17.1 COMPANY SNAPSHOT 158
18.17.2 REVENUE ANALYSIS 158
18.17.3 COMPANY SHARE ANALYSIS 159
18.17.4 PRODUCT PORTFOLIO 159
18.17.5 RECENT DEVELOPMENT 159
19 QUESTIONNAIRE 160
20 RELATED REPORTS 164

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 51
TABLE 2 MIDDLE EAST & AFRICA DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 53
TABLE 3 MIDDLE EAST & AFRICA STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 54
TABLE 4 MIDDLE EAST & AFRICA SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 5 MIDDLE EAST & AFRICA OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 6 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 59
TABLE 7 MIDDLE EAST & AFRICA PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 8 MIDDLE EAST & AFRICA PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 65
TABLE 10 MIDDLE EAST & AFRICA MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 11 MIDDLE EAST & AFRICA UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 12 MIDDLE EAST & AFRICA BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 13 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 73
TABLE 14 MIDDLE EAST & AFRICA ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 15 MIDDLE EAST & AFRICA NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 16 MIDDLE EAST & AFRICA MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 17 MIDDLE EAST & AFRICA ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 18 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 81
TABLE 19 MIDDLE EAST & AFRICA NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 20 MIDDLE EAST & AFRICA ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 21 MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 22 MIDDLE EAST & AFRICA VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 24 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 90
TABLE 25 MIDDLE EAST & AFRICA PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 26 MIDDLE EAST & AFRICA OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 27 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 97
TABLE 28 MIDDLE EAST & AFRICA HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 29 MIDDLE EAST & AFRICA HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 30 MIDDLE EAST & AFRICA CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 31 MIDDLE EAST & AFRICA COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 32 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 108
TABLE 33 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 108
TABLE 34 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 108
TABLE 35 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 108
TABLE 36 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 109
TABLE 37 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 109
TABLE 38 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 109
TABLE 39 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 109
TABLE 40 SOUTH AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110
TABLE 41 SOUTH AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 110
TABLE 42 SOUTH AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 110
TABLE 43 SOUTH AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 110
TABLE 44 SOUTH AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 111
TABLE 45 SOUTH AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 111
TABLE 46 SOUTH AFRICA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 111
TABLE 47 UAE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 112
TABLE 48 UAE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 112
TABLE 49 UAE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 112
TABLE 50 UAE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 112
TABLE 51 UAE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113
TABLE 52 UAE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 113
TABLE 53 UAE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 113
TABLE 54 SAUDI ARABIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 55 SAUDI ARABIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 114
TABLE 56 SAUDI ARABIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 114
TABLE 57 SAUDI ARABIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 114
TABLE 58 SAUDI ARABIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 115
TABLE 59 SAUDI ARABIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 115
TABLE 60 SAUDI ARABIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 61 REST OF MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116